Who We Are

TrueBinding Inc. is a clinical-stage biotherapeutics company pioneering a broad-spectrum healthspan platform. Rather than chasing downstream symptoms, we are dedicated to resolving the fundamental drivers of chronic inflammation and age-related decline. By targeting these upstream mechanisms, we are developing transformative treatments for neurodegeneration (Alzheimer's, Parkinson's), stroke, fibrosis, and oncology.

At the heart of our innovation is the TrueBinding™ platform, a proprietary discovery engine focused on the body's 'Master Switches' of disease and aging—most notably, Galectin-3 (Gal-3). By neutralizing Gal-3, our platform halts the toxic feedback loops of neuroinflammation, protein aggregation, and systemic tissue damage. This single, highly validated biological target powers our development of potentially game-changing monoclonal antibodies.

Our ultimate vision extends beyond treating late-stage disease; by restoring immune balance and protecting cellular integrity, TrueBinding is building the ultimate platform to extend human healthspan and longevity.